Press Release · Kibow Biotech
Kibow® Biotech Announces Availability of Renadyl® in Canada
Distributed by Elle Digest · Originally issued via PR Newswire

Expansion Brings Clinically Studied Kidney Probiotic to
More People Seeking to Maintain Kidney Health
EXTON, Pa., Nov. 19, 2026 — Kibow Biotech, a leading innovator in probiotic dietary supplements for kidney health, today announced the availability of its flagship product, Renadyl, in Canada, marking another important milestone in the company's mission to expand access to innovative, science-based kidney health solutions worldwide.
Developed through decades of research into the relationship between gut health and kidney function, Renadyl is a patented, clinically studied probiotic supplement scientifically formulated to help maintain healthy kidney function. Its unique approach focuses on the gut microbiome and its role in managing certain waste compounds that can place additional demands on the kidneys.
"Expanding Renadyl's availability into Canada represents an exciting step forward in our mission to make innovative kidney health solutions accessible to more people," said Mike Kane, President of Kibow Biotech. "Since 1997, we have been committed to advancing the science behind the gut-kidney connection and developing products that help people take a more proactive role in maintaining their kidney health. We are pleased to bring Renadyl to Canadians looking for additional ways to support their kidney health."
Chronic Kidney Disease (CKD) affects millions of people worldwide, creating a growing need for approaches that complement traditional kidney care. Renadyl offers a gut-based approach to kidney support, using specially selected probiotic strains to help metabolize certain waste compounds in the intestinal tract and support healthy kidney function.
"As a kidney health advocate and someone who understands firsthand the challenges of living with Chronic Kidney Disease, I am excited to see Renadyl becoming available to more people around the world," said James Fabin, founder of Dadvice TV and kidney health advocate. "People living with CKD are always looking for ways to take a more active role in their kidney health. Expanding access to products like Renadyl gives more people the opportunity to explore additional options and have informed conversations with their healthcare providers."
Renadyl features a proprietary blend of three probiotic strains delivering 45 billion colony-forming units (CFUs) per daily serving. Designed to work within the intestinal environment, these beneficial bacteria help support the body's natural processes for managing certain waste compounds while promoting a healthier gut environment.
The Canadian introduction builds on Kibow Biotech's longstanding commitment to scientific research, product innovation, and education about the important relationship between gut health and kidney function.
Renadyl is now available to Canadian consumers at Renadyl.ca, where they can purchase the product and learn more about its benefits and how it works.
Contact Information:
Michelle Adams
President
PRISM Marketing
614-989-6373
[email protected]
SOURCE Kibow Biotech
About Kibow Biotech, LLC
Founded October 1,1997, in Philadelphia, PA, the company's primary mission is to offer affordable, readily available, and easily administered nutritional supplements to support kidney health and other healthcare applications. Kibow Biotech's extensive scientific (R&D) and clinical data from multiple studies and scientific human clinical trials have been published in peer-reviewed scientific/medical journals (kibowbiotech.com/rd). The company's flagship product, Renadyl, is marketed around the world.